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KATZ, R. J., G. BALDRIGH1 AND B. J. CARROLL. Effects of nomifensine (HOE 984) upon psychomotor activity and 
intracranial self-stimulation in the rat. PHARMAC. BIOCHEM. BEHAV. 7(3) 269-272, 1977. - The effects of nomifensine 
maleate (HOE 984) were evaluated using two behavioral tasks. The drug produced dose related increases in both 
psychomotor activity and operant responding for brain stimulation reward. These results may point to possible 
psychostimulant properties for the drug. 
Activity Nomifensine Psychomotor Self stimulation Stimulant 
N O M I F E N S I N E  (HOE 984; 8 amino-2-methyl-4-phenyl-1,  
2, 3, 4 te t rahydroisoquinol ine)  is an exper imenta l  thymo-  
leptic drug with potent ia l  clinical ut i l i ty  and a number  of  
unusual pharmacological  propert ies  [2, 8, 9, 11, 14].  
Unlike many ant idepressant  drugs (e.g., imipramine and 
desipramine [ 4 ] )  which depress m o t o r  act ivi ty at least 
certain dosages of  nomifensine  may  in fact increase m o t o r  
activity (e.g., turning behavior,  s te reo typy  and general 
l ocomot ion  [ 2, 5, 8, 11 ] ). 
Since the drug may have an acute activating effect  in 
several behavioral  models  the present  tests a t t empted  to 
quant i fy  initial responses to drug adminis t ra t ion upon t w o  
tasks - p s y c h o m o t o r  activity upon an act ivi ty p la t form and 
intracranial self-st imulation.  This choice of  measures was 
in tended bo th  to supplement  previous reports  and to offer  
a prel iminary assessment of  this drug's potent ia l  psycho- 
s t imulant  propert ies ,  since psychos t imulan t  drugs are known 
to increase both  behaviors [ 12, 15, 20] .  
E X P E R I M E N T  1: P S Y C H O M O T O R  E F F E C T S  
METHOD 
Animals 
Thir ty- two adult male Sprague-Dawley rats obta ined 
locally (Charles River Farms, Portage, MI) and weighing 
2 5 0 - 4 8 0  g each were mainta ined on ad lib food (Wayne 
Lab blox)  and water,  and normal  day/n ight  cycles of  12 hr 
each (light onset and offset  were 8 and 20 hr  EST). Animals  
were housed in groups of  four. 
A ppara tus 
Animals were individually tested in 50 x 40 x 22 cm 
po lypropylene  cages (Scientific Products  Series 70) with a 
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bedding of  fresh pine chips. Cages were located upon field 
sensitive activity minot i rs  (Stoel t ing SA 1566, 1562, 1570) 
operat ing upon a selective m o d e  for the de tec t ion  of  gross 
body movement .  Four  moni to rs  calibrated to within 5% of 
each o ther  were in use at a given time. 
Drugs. Nomifensine  hydrogen  maleate  was injected as a 
suspension in 0, 2.5, 5.0, 10.0 mg/kg dosages. Dosages were 
based upon previous reports  [2, 5, 11] and all drugs were 
administered intraper i toneal ly  in a volume of 1 cc/kg in a 
0.9% saline vehicle. 
Procedure 
Animals were al lowed 60 min to habi tua te  to cages and 
ambient  noise. Fol lowing habi tua t ion  all rats were briefly 
removed and injected.  Recording cont inued for an 
addit ional  120min .  Ten minute  recording intervals were 
used th roughout  the entire 180 rain session. 
Analysis. Drug effects were evaluated via a Fr iedman 
2-way analysis of  variance [17] based upon the final 
120 min (i.e., drug per iod)  of  each recording session. 
RESULTS 
Results are presented in Fig. 1. It can be seen that  initial 
explora t ion  declined to a consistent  low level at 60 min. 
Fol lowing inject ion nomifensine treated groups showed a 
dose related increase in activity which was significant (x~ = 
194,  df  = 3 ; p < 0 . 0 5 ) .  
E X P E R I M E N T  2 
It is evident  from the first exper iment  that  nomifensine 
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FIG. 1. Effects of nomifensine upon motor activity (mean + SEM). 
has p s y c h o m o t o r  s t imulat ing propert ies.  This is consistent  
wi th  previous observat ions [5] .  Exper iment  2 evaluated the 
effects  of  nomifensine  upon responding mainta ined by 
rewarding brain s t imulat ion delivered to the medial  fore- 
brain bundle,  a task which is also facil i tated by a variety of  
s t imulants  [ 20] .  
METHOD 
Anirnals 
Sixteen rats equivalent  in descript ion to those employed  
in the first exper iment  were used. Fo r  recording purposes 
animals were housed individually.  
initial saline injected session was considered 100%. U tests 
were used to evaluate statistical differences [17] .  
RESULTS 
All e lectrode placements  were located in the caudal 
medial forebrain bundle with the major i ty  of  sites clustered 
in an area immedia te ly  dorsal to the substantial nigra. It 
may be seen in Fig. 2 that nomifensine facil i tated re- 
sponding for s t imulat ion and this was significant at the two 
highest levels of  drug (respective U scores for the three drug 
dosages were 13, 5, 3 with the critical (p<0 .05)  U = 12. 
Saline injected animals showed minor  and inconsistent  
changes across sessions. 
Apparatus  and Procedures 
The self-st imulation task of Wolf  et al. [24] was used for  
behavioral  testing. Surgical procedures ,  training, and 
apparatus were essentially similar to published reports  5 0 0  
[24] .  In the self-st imulation task displacement  of  an 
overhead panel  (a 14 × 16 cm steel plate located 14 cm 
from the cage f loor)  resulted in the delivery of a 0.3 sec ~ 4 0 0  
train of  a monopo la r  60 cps sinusoidal current  5 0 - 3 0 0  t~A to 
in in tensi ty  via a head m o u n t e d  brushing. At  the close of  ~ 3 0 0  
testing all animals were killed with  sodium pentobarbi ta l  n 
and the brains were perfused and f ixed for histologic to 
" '  2 0 0  n,- examination. Twen ty  ~ sections of  brain were examined 
after staining with  cresyl violet .  
Behavioral testing consisted of inject ion of  saline or drug I 0 0  
(dosages and inject ion procedures  were identical  to Ex- 
per iment  1) and recording total  responses for a 4 hr  period.  0 
Each animal was tested with several dose levels of  nomi-  
fensine, and a recovery period of  72 hr intervened be tween  
injections.  Gross observat ions of animals in Exper iment  1 
indicated behavioral  recovery from the st imulating effects  
of  the drug within 24 hr. 
Statistics. Since individual animals showed  widely 
differing albeit  consistent  rates of  response the data are 
presented as percentage t ransformed scores in which the 
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FIG. 2. Effects of nomifensine upon self stimulation (percent 
baseline + percent SEM)*; p<0.05. 
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G E N E R A L  DISCUSSION 
Nomifens ine  has been shown to increase p s y c h o m o t o r  
act ivi ty and intracranial  self-st imulat ion in rats. These 
results may have bo th  preclinical and clinical implicat ions.  
Looking first to their  preclinical significance, the present  
report  bo th  confirms and expands  previous observat ions 
regarding the drug's p s y c h o m o t o r  effects. One previous 
report ,  which specifically examined  general p s y c h o m o t o r  
pat terns  described biphasic effects  with respect to t ime and 
dosage, i.e., lower  dosages produced  an initial per iod of  
mo to r  inhibi t ion fol lowed by a later  onset  of  exci ta t ion  
[8] .  A consistent  l o c o m o t o r  act ivat ion is repor ted  after  
higher doses of  nomifensine [5 ,8] .  In the present  report  the 
p redominan t  effect  of  nomifensine  was activation.  Figure 1 
indicates also a slight initial m o t o r  depression at the lowest  
dosage level, which is consis tent  with the previous repor t  
[8] .  Similar biphasic effects  have been repor ted  for  a 
variety of direct and indirect ly acting dopamine  (DA) 
agonists (apomorphine  [ 1] b romocryp t ine  [ 18,19] and 
amantadine  [21 ,22] ) .  Since nomifensine is a po ten t  DA 
agonist [2 ,5] ,  the present  m o t o r  effects  may  be related to 
facil i tated t ransmit ter  release [9, 11, 14].  Direct  and 
indirect ly acting DA agonists have also been repor ted  to 
augment  self-st imulat ion [6, 7, 1 1, 13, 20, 23 ] .  In general a 
presynapt ic  releasing act ion produces a more  uni form 
increase in self-st imulat ion rates (e.g., [6, 7, 20] ) .  The 
un i formi ty  of  the present results may argue indirect ly  for a 
presynapt ic  m o d e  of  action, It should be stressed, however ,  
that nomifensine bears li t t le s tructural  similari ty to psycho-  
st imulants,  and upon  purely s tructural  criteria a direct  post  
synapt ic  m o d e  of  act ion cannot  be exc luded  [ 10].  Nomi-  
fensine differs f rom psychost imulants  clinically as well as 
s tructural ly,  since s t imulant  drugs are of  qui te  l imited 
ut i l i ty  in the t r ea tment  of  endogenous  depression. Nomi-  
fensine is therefore  unique  in a variety of  ways - it is bo th  
clinically effect ive,  s t ructural ly unique,  and possibly related 
to indirect ly acting sympa thomimet i c s  on psychopharmaco-  
logical grounds (e.g., [5 ,9 ] ,  also the present  tests). 
Our resu l t s  also have a number  of  clinical implicat ions;  
on the one hand,  they suggest that  nomifensine  is l ikely to 
produce  an initial act ivat ion and m o o d  elevat ion in clinical 
use - this p roper ty  might  prove useful in the t rea tment  of  
m o o d  disorders, especially since most  thymolep t i c  agents 
show a delayed onset  of  action,  of ten lasting up to two 
weeks. On the o ther  hand,  however ,  it should be stressed 
that  nomifensine ,  which resembles psychost imulants  upon  
several behavioral  tests may also share wi th  them a 
potent ia l  for abuse. While most  antidepressants  lack serious 
abuse potent ia l ,  this has been repor ted  occasionally wi th  
the monoamine  oxidase inhibi tors  [ 16].  Our results suggest 
that  the abuse potent ia l  of nomifensine  should be evaluated 
quite  carefully.  
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